Eaton and Siemens Energy Join Forces to Provide Power and Technology to Accelerate the Delivery of New Data Center Capacity
Integrated modular data center construction will bring capacity online at speed to meet growing global demand for AI and cloud computing
Standardized on-site power generation is key to accelerate the development of new data centers
Article content
Article content
DUBLIN & BERLIN — Intelligent power management company Eaton, and Siemens Energy, one of the world's leading energy technology companies, have announced a fast-track approach to building data centers with integrated onsite power. They will address urgent market needs by offering reliable grid-independent energy supplies and standardized modular systems to facilitate swift data center construction and deployment.
Article content
Eaton and Siemens Energy join forces to provide power and technology to accelerate the delivery of new data center capacity.
Article content
The collaboration will enable simultaneous construction of data centers and associated on-site power generation with grid connection and the integration of renewables to meet regional regulatory requirements, if required. This will provide data center owners and developers with choices they don't have at present to enable them to build and run new data centers.
Article content
Siemens Energy's modular and scalable power plant concept is tailored to the specific needs of data center operators. The standard configuration generates 500 megawatts (MW) of electricity, featuring highly efficient SGT-800 gas turbines, redundancy and additional battery storage systems, ensuring the highest reliability. Based on its modular approach, the size of the plant can be scaled up and down. In the future, it can also operate in a carbon-neutral manner, provided hydrogen is available and part of the data center's sustainability strategy. The Siemens Energy concept also includes an optional emission-free clean air grid connection to be installed either during construction or as a retrofit. This feature would enable data centers to provide grid services.
Article content
Eaton will provide customers with electrical equipment such as medium voltage switchgear, low voltage switchgear, UPS, busways, structural support, racks and containment systems, engineering services and the software offerings needed to protect and enable IT loads from the medium-voltage grid to the chip and help accelerate building and commissioning data centers with skidded and modular designs.
Article content
Cyrille Brisson, global segment leader, Data Centers, Eaton, said: 'Our approach of letting customers pick the right balance of energy sources is very flexible and construction to start-up time is swift with options to reduce emissions in both the short and long term. Crucially, our approach offers data center owners and developers the opportunity to build capacity and bring it online fast in any location where they have land available that is close to gas, water and fiber.'
Article content
Andreas Pistauer, global head of sales, Siemens Energy's Gas Services Business Area, said: 'We offer hyperscalers, co-locators and investors a unique package, enabling them to reduce the time-to-market by up to two years in many places which leads to significant revenue gains. Our power plant design is built with redundancy, eliminating the need for backup diesel generators, and reducing CO 2 emissions by about 50 percent.'
Article content
About Eaton
Article content
Eaton is an intelligent power management company dedicated to protecting the environment and improving the quality of life for people everywhere. We make products for the data center, utility, industrial, commercial, machine building, residential, aerospace and mobility markets. We are guided by our commitment to do business right, to operate sustainably and to help our customers manage power ─ today and well into the future. By capitalizing on the global growth trends of electrification and digitalization, we're helping to solve the world's most urgent power management challenges and building a more sustainable society for people today and generations to come.
Article content
Founded in 1911, Eaton has continuously evolved to meet the changing and expanding needs of our stakeholders. With revenues of nearly $25 billion in 2024, the company serves customers in more than 160 countries. For more information, visit www.eaton.com. Follow us on LinkedIn.
Article content
Siemens Energy is one of the world's leading energy technology companies. The company works with its customers and partners on energy systems for the future, thus supporting the transition to a more sustainable world. With its portfolio of products, solutions and services, Siemens Energy covers almost the entire energy value chain – from power and heat generation and transmission to storage. The portfolio includes conventional and renewable energy technology, such as gas and steam turbines, hybrid power plants operated with hydrogen, and power generators and transformers. Its wind power subsidiary Siemens Gamesa makes Siemens Energy a global market leader for renewable energies. An estimated one-sixth of the electricity generated worldwide is based on technologies from Siemens Energy. Siemens Energy employs around 101,000 people worldwide in more than 90 countries and generated revenue of €34.5 billion in fiscal year 2024.
Article content
Article content
Article content
Article content
Contacts
Article content
Eaton
Angela Swann
Global PR & Policy Communications Manager
angelaswann@eaton.com
mobile +44 7773 198113
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
7 hours ago
- Globe and Mail
Cresco Labs Closes $325 Million Senior Secured Term Loan Refinancing
Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (' Cresco Labs ' or the ' Company '), today announced the closing of its previously announced refinancing of the Company's senior secured credit facility. The new US$325 million senior secured term loan bears an interest rate of 12.5% per annum and matures on August 13, 2030. It replaces the Company's prior US$360 million facility, reducing total debt, extending the maturity to 2030, and providing enhanced flexibility to prepay up to US$125 million at a reduced premium. 'This transaction is another milestone in our disciplined approach to capital management,' said Charlie Bachtell, CEO of Cresco Labs. 'We have strengthened our balance sheet and removed near-term refinancing risk. With this foundation in place, we can remain focused on executing our growth strategy.' Proceeds from the new facility, together with cash on hand, were used to repay in full the existing term loan. The facility contains no equity or convertible features and includes customary financial and operational covenants. A.G.P. Canada Investments ULC and Cormark Securities Inc. acted as lead financial advisors and lead arrangers on the transaction. The lead lenders were advised by Paul Hastings LLP. About Cresco Labs Inc. Cresco Labs' mission is to normalize and professionalize the cannabis industry through a CPG approach to building national brands and a customer-focused retail experience, while acting as a steward for the industry on legislative and regulatory-focused initiatives. As a leader in cultivation, production, and branded product distribution, the Company is leveraging its scale and agility to grow its portfolio of brands that include Cresco, High Supply, FloraCal, Good News, Wonder Wellness Co., Mindy's, and Remedi, on a national level. The Company also operates highly productive dispensaries nationally under the Sunnyside brand that focus on building patient and consumer trust and delivering ongoing education and convenience in a wonderfully traditional retail experience. Through year-round policy, community outreach and SEED initiative efforts, Cresco Labs embraces the responsibility to support communities through authentic engagement, economic opportunity, investment, workforce development, and legislative initiatives designed to create the most responsible, respectable and robust cannabis industry possible. Learn more about Cresco Labs' journey by visiting or following the Company on Facebook, X or LinkedIn. Forward-Looking Statements This press release contains 'forward-looking information' within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute 'forward-looking statements' within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995 (collectively, 'forward-looking statements'). Such forward-looking statements are not representative of historical facts or information or current condition but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company's control. Generally, such forward-looking statements can be identified by the use of forward-looking terminology such as, 'may,' 'will,' 'should,' 'could,' 'would,' 'expects,' 'plans,' 'anticipates,' 'believes,' 'estimates,' 'projects,' 'predicts,' 'potential,' or 'continue,' or the negative of those forms or other comparable terms and in this press release includes statements relating to, among other things: any prepayments under the new facility; access to capital; and the Company executing on its multi-year growth plan. The Company's forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including but not limited to those risks discussed under 'Risk Factors' in the Company's Annual Information Form for the year ended December 31, 2024, filed on SEDAR+ and EDGAR, other documents filed by the Company with Canadian securities regulatory authorities; and other factors, many of which are beyond the control of the Company. Readers are cautioned that the foregoing list of factors is not exhaustive. Because of these uncertainties, you should not place undue reliance on the Company's forward-looking statements. No assurances are given as to the future trading price or trading volumes of Cresco Labs' shares, nor as to the Company's financial performance in future financial periods. The Company does not intend to update any of these factors or to publicly announce the result of any revisions to any of the Company's forward-looking statements contained herein, whether as a result of new information, any future event, or otherwise. Except as otherwise indicated, this press release speaks as of the date hereof. The distribution of this press release does not imply that there has been no change in the affairs of the Company after the date hereof or create any duty or commitment to update or supplement any information provided in this press release or otherwise.
Globe and Mail
8 hours ago
- Globe and Mail
Evotec SE Reports H1 2025 Results: Strong Progress on Strategy Execution
Strategy for sustainable profitable growth progressing as planned with improving revenue mix and ahead-of-plan cost reductions Reporting segment formerly known as Shared R&D renamed to Discovery & Preclinical Development ("D&PD") to better reflect strategic focus Group revenues of € 371.2 m (-5%); D&PD (-11%) continues to see soft demand;Just - Evotec Biologics ("JEB"; +16%) exceeding expectations driven by broadened customer base Key progress in collaborations with Bristol Myers Squibb ("BMS") on targeted protein degradation and neuroscience Evolution of strategic partnership with Sandoz announced on 30 July HAMBURG, DE / ACCESS Newswire / August 13, 2025 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) today announced financial results for H1 2025, demonstrating clear progress in the implementation of its new strategy for sustainable and profitable growth; highlighting Just - Evotec Biologics' strong growth as it transitions to an asset-lighter model. Dr Christian Wojczewski, Chief Executive Officer of Evotec, said: "We are firmly on track with the execution of our strategy: Evotec is making meaningful strides toward sustainable and profitable growth. JEB maintained its strong growth trajectory with first half revenues in excess of € 100 m, and the evolution of our strategic partnership with Sandoz is testament to its bright future as a scalable technology provider with a more capital-efficient model. Our base business in D&PD continues to face soft demand, but we see strong progress in core collaborations and are systematically expanding our platform technologies, such as our Molecular Patient Database. I am confident that our unrelenting focus on technology and science leadership will continue to drive tangible impact in the future". Discovery & Preclinical Development impacted by soft market; Just - Evotec Biologics continues strong growth momentum Group revenues decreased by 5.0% to € 371.2 m (6M 2024: € 390.8 m) Total D&PD revenues decreased by 11.0% to € 269.0 m (6M 2024: € 302.4 m) with performance reflecting soft drug discovery market environment and phasing of revenues with Pharma partners; recovery of D&PD market expected as early as 2026 Just - Evotec Biologics revenues increased by 16% to € 102.2 m (6M 2024: € 88.9 m); strong growth with non-Sandoz / non-DoD customers Adjusted Group EBITDA totalled € (1.9) m (6M 2024: € (0.5) m) in-line with expectations due to strong cost control across the business Execution of strategy to refocus and deliver sustainable profitable growth fully on track Cost savings expected to exceed targets announced during the Q1 2025 results call on 06 May 2025 Implementation of strategy and new organization initiated Events after Period-End On 30 July 2025, Evotec announced the signing of a non-binding agreement on the potential sale of Just - Evotec Biologics EU - which owns the biologics manufacturing facility in Toulouse, France and to grant access to its proprietary platform for integrated development and advanced continuous manufacturing of biologics via a technology license Deal terms include purchase price of the site for around US$ 300 m in cash and additional further technology related consideration, future development revenues, milestones and product royalties Planned transaction validates JEB's end-to-end continuous manufacturing technology and marks milestone in planned transition of JEB to asset-lighter model that better scales and leverages its technology and IP Closing of the planned transaction remains subject to completion of the relevant information and consultation processes with employees and their representatives, final contractual agreements and to meeting regulatory requirements, expected in the fourth quarter Progress in key strategic collaborations Significant progress in strategic protein degradation collaboration with BMS triggering performance-based and program-based payments of in total US$ 75 m Key progress in neuroscience collaboration with BMS triggering a research payment of US$ 20 m Grant awarded from The Gates Foundation ("GF") to support the development of next-generation treatment regimens for tuberculosis ("TB") Evotec joined NURTuRE-AKI consortium, expanding Molecular Patient Database and improving leadership position in the field of kidney disease Evotec welcomed the FDA's "Roadmap to Reducing Animal Testing in Preclinical Safety Studies" which is aligned with Evotec's long-term strategic investment in New Approach Methodologies (NAMs) and its 30+ year commitment to ethics and the principles of 3-Rs (Replacement, Reduction and Refinement) Guidance for full-year 2025 Group revenues expected in a range of € 760 - 800 m (2024: € 797.0 m) R&D expenditures are expected in a range of € 40 - 50 m (2024: € 50.9 m) Adjusted Group EBITDA is expected to reach € 30 - 50 m (2024: € 22.6 m) More detailed information and financial tables are available in the half-year report published on the Evotec website under the following link: Webcast/Conference Call The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The conference call will be held in English. Webcast details Date: Wednesday, 13 August 2025 Time: 2.00 pm CEST (1.00 pm BST, 8.00 am EDT) To join the audio webcast and to access the presentation slides, please register via this link. The on-demand version of the webcast will be available on our website: Financial Publications - Evotec. Conference call details To join via phone, please pre-register via this link. You will then receive a confirmation email with dedicated dial-in details such as telephone number, access code and PIN to access the call. A simultaneous slide presentation for participants dialing in via phone is available under this link. About Evotec SE Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec's global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. For additional information please go to and follow us on X/Twitter @Evotec and LinkedIn. Forward-looking statements This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. For further information, please contact: Investor Relations SOURCE: Evotec SE View the original press release on ACCESS Newswire
Globe and Mail
14 hours ago
- Globe and Mail
Micron Eyes High-Teen DRAM Demand Growth: Is It Sustainable?
Micron Technology, Inc. MU forecasts industry DRAM bit demand to grow in the high-teen percentage range in 2025, mainly driven by the rising demand for AI-driven applications. The memory chip maker's DRAM revenues climbed 51% year over year and 15% sequentially to $7.1 billion and represented 76% of total sales in the third quarter of fiscal 2025. Record sales in the data center end market and accelerating High Bandwidth Memory ('HBM') adoption mainly drove DRAM revenues higher. The growing adoption of AI servers is reshaping the DRAM market as these systems require significantly more memory than traditional servers. This is boosting demand for both high-capacity DIMMs (Dual In-line Memory Module) and low-power server DRAM. Micron is capitalizing on this trend with its leadership in DRAM technology and a strong product roadmap that includes HBM4, slated for volume production in 2026. Tight supply conditions are another factor supporting the optimistic outlook for Micron's DRAM products. The company intends to keep non-HBM DRAM bit supply growth below industry demand to maintain pricing discipline and profitability. With AI adoption expanding across data center, mobile and automotive markets, Micron appears well-positioned to benefit from robust DRAM demand in the near term. The Zacks Consensus Estimate for fiscal 2025 indicates that DRAM revenues will soar approximately 59% year over year to $27.95 billion. How Do Micron's Rivals Stack Up in the Memory Chip Race? Although there are no U.S. stock exchange-listed direct competitors for MU in the memory chip space, Intel Corporation INTC and Broadcom Inc. AVGO play key roles in the HBM supply chain and AI hardware ecosystem. Intel is developing its AI accelerators that rely on high-performance memory like HBM. Although Intel doesn't manufacture HBM chips, its Gaudi AI chips will require a robust HBM supply, and any shift in memory partnerships could impact Micron's position. Meanwhile, Broadcom designs custom application-specific integrated circuits used in AI infrastructure that often include integrated HBM. As demand for Broadcom's AI chips grows, it could influence how HBM suppliers like Micron allocate their future supply. Micron's Price Performance, Valuation and Estimates Shares of Micron Technology have risen around 51.8% year to date compared with the Zacks Computer – Integrated Systems industry's gain of 27.4%. Image Source: Zacks Investment Research From a valuation standpoint, MU trades at a forward price-to-sales ratio of 3, lower than the industry's average of 3.72. The Zacks Consensus Estimate for Micron Technology's fiscal 2025 and 2026 earnings implies a year-over-year increase of approximately 497.7% and 57.9%, respectively. Estimates for fiscal 2025 and 2026 have been revised upward in the past 60 days. Image Source: Zacks Investment Research Micron Technology currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. See our %%CTA_TEXT%% report – free today! 7 Best Stocks for the Next 30 Days Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Intel Corporation (INTC): Free Stock Analysis Report Micron Technology, Inc. (MU): Free Stock Analysis Report Broadcom Inc. (AVGO): Free Stock Analysis Report
